Merck Global Health Innovation Fund and Bristol-Myers Squibb have provided the final tranche for PathAI’s $75m series B round, adding to an earlier commitment from LabCorp.
US-based pathology research technology developer PathAI closed a $75m series B round yesterday after securing a final tranche from pharmaceutical firms Merck & Co and Bristol-Myers Squibb.
Merck & Co contributed through its Global Health Innovation Fund (GHIF). The size of the extension was not revealed.
PathAI previously obtained an extension of unspecified size from laboratory services provider LabCorp in July 2019, adding to a $60m initial series B tranche co-led by General Atlantic and General Catalyst in April…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
